Amundi Pioneer Asset Management Inc. Has $52.10 Million Stock Holdings in AstraZeneca plc (NYSE:AZN)

Amundi Pioneer Asset Management Inc. lifted its holdings in shares of AstraZeneca plc (NYSE:AZN) by 18.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,288,720 shares of the company’s stock after buying an additional 201,645 shares during the period. Amundi Pioneer Asset Management Inc. owned 0.05% of AstraZeneca worth $52,103,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the stock. Investors Asset Management of Georgia Inc. GA ADV grew its position in shares of AstraZeneca by 1.5% during the 1st quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 20,315 shares of the company’s stock valued at $821,000 after buying an additional 300 shares during the last quarter. Rehmann Capital Advisory Group boosted its stake in AstraZeneca by 13.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 2,893 shares of the company’s stock valued at $110,000 after purchasing an additional 336 shares during the period. Commonwealth Equity Services LLC boosted its stake in AstraZeneca by 0.3% during the 4th quarter. Commonwealth Equity Services LLC now owns 124,281 shares of the company’s stock valued at $4,720,000 after purchasing an additional 386 shares during the period. Oppenheimer & Co. Inc. boosted its stake in AstraZeneca by 1.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 28,007 shares of the company’s stock valued at $1,132,000 after purchasing an additional 446 shares during the period. Finally, Mckinley Capital Management LLC Delaware boosted its stake in AstraZeneca by 0.8% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 61,475 shares of the company’s stock valued at $2,485,000 after purchasing an additional 479 shares during the period. 18.79% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:AZN traded down $0.61 during trading on Friday, reaching $40.12. The company had a trading volume of 3,709,634 shares, compared to its average volume of 2,030,993. The business’s fifty day moving average is $40.24. The firm has a market cap of $103.16 billion, a price-to-earnings ratio of 11.60, a PEG ratio of 1.36 and a beta of 0.53. AstraZeneca plc has a twelve month low of $35.30 and a twelve month high of $43.29. The company has a debt-to-equity ratio of 1.48, a current ratio of 0.75 and a quick ratio of 0.58.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Friday, April 26th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $5.47 billion during the quarter, compared to analyst estimates of $5.40 billion. AstraZeneca had a net margin of 10.75% and a return on equity of 37.91%. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.48 EPS. On average, research analysts forecast that AstraZeneca plc will post 1.78 EPS for the current year.

A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Great Portland Estates from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Cowen raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $42.00 to $48.00 in a research note on Monday, April 1st. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Pareto Securities raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, April 29th. Finally, UBS Group set a $169.00 target price on shares of M&T Bank and gave the company a “hold” rating in a research note on Tuesday, April 2nd. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $45.29.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What is the Russell 2000 Index?

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.